

NCDappendix3

From: George Hayes <George.Hayes@cancer.org.uk>
Sent: Wednesday, June 22, 2022 9:02 AM
To: NCDappendix3
Subject: [EXT] Feedback on Draft updated appendix 3 of the WHO NCD Action Plan 2013-30

Dear WHO NCD Action Plan Team,

Cancer Research UK is pleased to participate in the initial non-state actor consultation on the discussion paper for the draft Updated Appendix 3 of the Global NCD Action Plan 2013-30. We appreciate the dialogue that has been encouraged by WHO to enable NSA's to communicate their feedback on the text effectively, and we look forward to feeding into the process of reviewing the second draft when it is published later in the summer.

We particularly welcome the continued strong focus on tobacco control as a core pillar of prevention of NCDs, including cancer. The update of six original interventions on tobacco control from the 2017 text is encouraging as it suggests the best-buy interventions are being kept fit for purpose with the emergence of new evidence. We also are pleased that action against cervical cancer and HPV remains prominent in the cancer section of the appendix.

While we agree that expanding the full range of policy interventions is a positive step, we would encourage the retention of the "Best Buy" terminology in the final document, and feel that this is a clearer and more effective advocacy tool than the current approach of using the banded cost effectiveness ratios.


Thank you for the opportunity to feedback, and we look forward to the next draft in the coming months.

Best wishes,

George Hayes (he/him)
Global Partnerships & Advocacy Manager
Cancer Research UK

2 Redman Place | London | E20 1JQ

[Web](#) | [Facebook](#) | [Twitter](#)



NOTICE AND DISCLAIMER This e-mail (including any attachments) is intended for the above-named person(s). If you are not the intended recipient, notify the sender immediately, delete this email from your system and do not

disclose or use for any purpose. We may monitor all incoming and outgoing emails in line with current legislation. We have taken steps to ensure that this email and attachments are free from any virus, but it remains your responsibility to ensure that viruses do not adversely affect you. Cancer Research UK Registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247) A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered Office Address: 2 Redman Place, London, E20 1JQ